Medulloblastoma is the most frequent malignant childhood brain tumor with a high morbidity. Identification of new therapeutic targets would be instrumental in improving patient outcomes. We evaluated the expression of the tumor-associated antigen PRAME in biopsies from 60 patients with medulloblastoma. PRAME expression was detectable in 82% of tissues independent of molecular and histopathologic subgroups. High PRAME expression also correlated with worse overall survival. We next investigated the relevance of PRAME as a target for immunotherapy. Medulloblastoma cells were targeted using genetically modified T cells with a PRAME-specific TCR (SLL TCR T cells). SLL TCR T cells efficiently killed medulloblastoma HLA-A-02+ DAOY cells as well as primary HLA-A-02+ medulloblastoma cells. Moreover, SLL TCR T cells controlled tumor growth in an orthotopic mouse model of medulloblastoma. To prevent unexpected T-cell- related toxicity, an inducible caspase-9 (iC9) gene was introduced in frame with the SLL TCR; this safety switch triggered prompt elimination of genetically modified T cells. Altogether, these data indicate that T cells genetically modified with a high-affinity, PRAME-specific TCR and iC9 may represent a promising innovative approach for treating patients with HLA-A-02+ medulloblastoma. Significance: These findings identify PRAME as a medulloblastoma tumor-associated antigen that can be targeted using genetically modified T cells.

Orlando, D., Miele, E., De Angelis, B., Guercio, M., Boffa, I., Sinibaldi, M., Po, A., Caruana, I., Abballe, L., Carai, A., Caruso, S., Camera, A., Moseley, A., Hagedoorn, R. S., Heemskerk, M. H. M., Giangaspero, F., Mastronuzzi, A., Ferretti, E., Locatelli, F., Quintarelli, C., Adoptive immunotherapy using prame-specific t cells in medulloblastoma, <<CANCER RESEARCH>>, 2018; 78 (12): 3337-3349. [doi:10.1158/0008-5472.CAN-17-3140] [https://hdl.handle.net/10807/229971]

Adoptive immunotherapy using prame-specific t cells in medulloblastoma

Locatelli, Franco
Penultimo
Writing – Review & Editing
;
2018

Abstract

Medulloblastoma is the most frequent malignant childhood brain tumor with a high morbidity. Identification of new therapeutic targets would be instrumental in improving patient outcomes. We evaluated the expression of the tumor-associated antigen PRAME in biopsies from 60 patients with medulloblastoma. PRAME expression was detectable in 82% of tissues independent of molecular and histopathologic subgroups. High PRAME expression also correlated with worse overall survival. We next investigated the relevance of PRAME as a target for immunotherapy. Medulloblastoma cells were targeted using genetically modified T cells with a PRAME-specific TCR (SLL TCR T cells). SLL TCR T cells efficiently killed medulloblastoma HLA-A-02+ DAOY cells as well as primary HLA-A-02+ medulloblastoma cells. Moreover, SLL TCR T cells controlled tumor growth in an orthotopic mouse model of medulloblastoma. To prevent unexpected T-cell- related toxicity, an inducible caspase-9 (iC9) gene was introduced in frame with the SLL TCR; this safety switch triggered prompt elimination of genetically modified T cells. Altogether, these data indicate that T cells genetically modified with a high-affinity, PRAME-specific TCR and iC9 may represent a promising innovative approach for treating patients with HLA-A-02+ medulloblastoma. Significance: These findings identify PRAME as a medulloblastoma tumor-associated antigen that can be targeted using genetically modified T cells.
2018
Inglese
Orlando, D., Miele, E., De Angelis, B., Guercio, M., Boffa, I., Sinibaldi, M., Po, A., Caruana, I., Abballe, L., Carai, A., Caruso, S., Camera, A., Moseley, A., Hagedoorn, R. S., Heemskerk, M. H. M., Giangaspero, F., Mastronuzzi, A., Ferretti, E., Locatelli, F., Quintarelli, C., Adoptive immunotherapy using prame-specific t cells in medulloblastoma, <<CANCER RESEARCH>>, 2018; 78 (12): 3337-3349. [doi:10.1158/0008-5472.CAN-17-3140] [https://hdl.handle.net/10807/229971]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/229971
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 56
social impact